Take Photo / Shutterstock.com
The English High Court has affirmed the validity of Eli Lilly’s European patent covering the use of the drug Strattera (atomoxetine), used to treat attention-deficit hyperactivity disorder (ADHD).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
English High Court; ADHD; Eli Lilly; ADHD; generics; SPCs
